SCHEMBL9820283

SCHEMBL9820283

CNc1cc(F)cc(NC)c1[N+](=O)[O-]

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.46
MAPT P10636 4/20 0.46
HTT P42858 3/20 0.46
LMNA P02545 3/20 0.46
POLB P06746 2/20 0.46
KMT2A Q03164 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46
MAPK1 P28482 1/20 0.46
OPRD1 P41143 1/20 0.46
OPRK1 P41145 1/20 0.46
RAB9A P51151 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
TLR9 Q9NR96 1/20 0.46
GPR55 Q9Y2T6 1/20 0.46
HCAR3 P49019 1/20 0.39
ARNT P27540 1/20 0.37
EPAS1 Q99814 1/20 0.37
RECQL P46063 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL103325 0.90 MAPT (0.43) ALDH1A1MAPTHTTLMNAPOLB
SCHEMBL18408922 0.87 MAPT (0.41) ALDH1A1MAPTHTTLMNAPOLB
SCHEMBL21639463 0.84 MAPT (0.39) ALDH1A1MAPTHTTLMNAPOLB
SCHEMBL21639469 0.83 MAPT (0.38) ALDH1A1MAPTHTTLMNAPOLB
SCHEMBL34476073 0.80 GRIN2D (0.42) ALDH1A1MAPTHTTLMNAPOLB
SCHEMBL9771699 0.79 ALDH1A1 (0.54) ALDH1A1MAPTHTTLMNAPOLB
SCHEMBL944995 0.79 ALDH1A1 (0.43) ALDH1A1MAPTHTTLMNAPOLB
SCHEMBL29785632 0.78 ATM (0.37) ALDH1A1MAPTHTTLMNAPOLB
SCHEMBL30046277 0.77 ALDH1A1 (0.42) ALDH1A1MAPTHTTLMNAPOLB
SCHEMBL27162953 0.77 ALDH1A1 (0.42) ALDH1A1MAPTHTTLMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3279187-B1 9-MEMBERED FUSED RING DERIVATIVE SHIONOGI & CO (JP) 2021-06-02 EP disclosed
EP-3670496-A2 ACC2 INHIBITORS Shionogi&Co., Ltd. (JP) 2020-06-24 EP disclosed
US-20190144396-A1 9-MEMBERED FUSED RING DERIVATIVE SHIONOGI & CO., LTD. (JP) 2019-05-16 US disclosed
US-10233156-B2 9-membered fused ring derivative SHIONOGI & CO., LTD. (JP) 2019-03-19 US disclosed
US-20180079727-A1 9-MEMBERED FUSED RING DERIVATIVE SHIONOGI & CO., LTD. (JP) 2018-03-22 US disclosed
US-20160257641-A1 NOVEL ALKYLENE DERIVATIVES SHIONOGI & CO., LTD. (JP) 2016-09-08 US disclosed
EP-3059225-A1 NOVEL ALKYLENE DERIVATIVE Shionogi & Co., Ltd. (JP) 2016-08-24 EP disclosed
EP-0303826-B1 SUBSTITUTED 2-NITRO METAPHENYLENE DIAMINES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN DYEING KERATINOUS FIBRES AND ESPECIALLY HUMAN HAIR L'OREAL (FR) 1991-02-27 EP disclosed
US-4863482-A FROM A TRIHALONITROBENZENE L'OREAL (FR) 1989-09-05 US disclosed
EP-0303826-A1 Substituted 2-nitro metaphenylene diamines, process for their preparation and their use in dyeing keratinous fibres and especially human hair L'OREAL (FR) 1989-02-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180079727-A1 9-MEMBERED FUSED RING DERIVATIVE ACSS2, AGTR2, ACSL3 ALDH1A1 365/4885MAPT 4147/4885HTT 4627/4885
US-20190144396-A1 9-MEMBERED FUSED RING DERIVATIVE ACSS2, AGTR2, ACSL3 ALDH1A1 365/4885MAPT 4147/4885HTT 4627/4885
US-10233156-B2 9-membered fused ring derivative AGTR2, ACSS2, ACSL3 ALDH1A1 362/4885MAPT 3915/4885HTT 4571/4885
US-20160257641-A1 NOVEL ALKYLENE DERIVATIVES ACSS2, ACACB, ADCY2 ALDH1A1 288/4885MAPT 4052/4885HTT 4159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.